The aim of this study was to investigate the immunomodulatory capacity of native and Fe(II)-exposed intravenous immune globulin (IVIg) in multiple low dose streptozotocin-induced diabetes and to delineate the mechanisms of their influence on immune cell functions. Optimal doses (200–600mg/kg) of IVIg prevented the development of hyperglycemia, glycosuria and attenuated mononuclear cell infiltration in pancreatic islets. Fe(II) exposure of IVIg decreased their optimal therapeutic dose to 100mg/kg which significantly decreased the serum levels of proinflammatory cytokines compared to the same dose of native IVIg. This was accompanied by lower numbers of TNF-α, IFN-γ and IL-17 producing CD4+ T cells and increased frequencies of CD4+IL-10+ and CD4+IL-4+ T cells in the pancreatic lymph nodes and islets on day 16 after diabetes induction. Ferrous ion-exposed IVIg enhanced the bias towards Th2 response while the regulatory Foxp3+ T cells were not affected.
NegiVSElluruSSibérilS. Intravenous immunoglobulin: An update on the clinical use and mechanisms of action. J Clin Immunol2007; 27:233–45.
2.
NimmerjahnFRavetchJV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol2008; 26:513–33.
3.
GoldRStangelMDalakasMC. Drug insight: The use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol2007; 3:36–44.
4.
BayryJLacroix-DesmazesSKazatchkineMDKaveriSV. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: Rationale and mechanisms of action. Nat Clin Pract Rheumatol2007; 3:262–72.
5.
EphremAChamatSMiquelC. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: A critical factor in controlling experimental autoimmune encephalomyelitis. Blood2008; 111:715–22.
6.
DimitrovJDPashovADVassilevTL. Antibody polyspecificity: What does it matter. In: Natural Antibodies. LutzH., ed. Landes Biosciences. Austin, TX, USA, 2012; p. 213–26.
7.
MihaylovaNMDimitrovJDDjoumerska-AlexievaIKVassilevTL. Inflammation-induced enhancement of IgG immunoreactivity. Inflamm Res2008; 57:1–3.
8.
Djoumerska-AlexievaIKDimitrovJDNachevaJKaveriSVVassilevTL. Protein destabilizing agents induce polyreactivity and enhanced immunomodulatory activity in IVIg preparations. Autoimmunity2009; 42:365–7.
9.
DimitrovJDIvanovskaNDLacroix-DesmazesSDoltchinkovaVRKaveriSVVassilevTL. Ferrous ions and reactive oxygen species increase antigen-binding and anti-inflammatory activities of immunoglobulin. G J Biol Chem2006; 281:439–46.
10.
BouvetJPStahlDRoseSQuanCPKazatchkineMDKaveriSV. Induction of natural autoantibody activity following treatment of human immunoglobulin with dissociating agents. J Autoimmun2001; 16:163–72.
11.
McMahonMJO'KennedyR. Polyreactivity as an acquired artefact, rather than a physiologic property, of antibodies: Evidence that monoreactive antibodies may gain the ability to bind to multiple antigens after exposure to low pH. J Immunol Methods2000; 241:1–10.
12.
St-AmourILarocheABazinRLemieuxR. Activation of cryptic IgG reactive with BAFF, amyloid beta peptide and GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins. Clin Immunol2009; 133:52–60.
13.
DimitrovJDRoumeninaLTDoltchinkovaVRMihaylovaNMLacroix-DesmazesSKaveriSVVassilevTL. Antibodies use hema as a cofactor to extend their pathogen elimination activity and to acquire new effector functions. J Biol Chem2007; 282:26696–706.
14.
PavlovicSZdravkovicNDimitrovJDDjukicAArsenijevicNVassilevTLLukicML. Intravenous immunoglobulins exposed to heme (heme IVIG) are more efficient than IVIG in attenuating autoimmune diabetes. Clin Immunol2011; 138:162–71.
15.
Mensah-BrownEPShahinAAl-ShamisiMWeiXLukicML. IL-23 leads to diabetes induction after subdiabetogenic treatment with multiple low doses of streptozotocin. Eur J Immunol2006; 36:216–23.
16.
DelaneyCADungerADi MatteoMCunninghamJMGreenMHGreenIC. Comparison of inhibition of glucose-stimulated insulin secretion in rat islets of Langerhans by streptozotocin and methyl and ethyl nitrosoureas and methanesulphonates. Lack of correlation with nitric oxide-releasing or O6-alkylating ability. Biochem Pharmacol1995; 50:2015–20.
17.
ElsnerMGuldbakkeBTiedgeMMundayRLenzenS. Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin. Diabetologia2000; 43:1528–33.
18.
SzkudelskiT. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res2001; 50:537–46.
19.
HeroldKCBlochTNVezysV. Diabetes induced with low doses of streptozotocin is mediated by V beta 8.2+ T-cells. Diabetes1995; 44:354–9.
20.
HeroldKCVezysVSunQ. Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol1996; 156:3521–7.
21.
DimitrovJDPlanchaisCKangJPashovAVassilevTLKaveriSVLacroix-DesmazesS. Heterogeneous antigen recognition behavior of induced poly-specific antibodies. Biochem Biophys Res Commun2010; 398:266–71.
22.
VassilevTL. Use of ferrous ions for increasing the immunoreactivity of immunoglobulin preparations. 2006; pat. no. WO2006056031;
23.
HeinzeE. Immunoglobulins in children with autoimmune diabetes mellitus. Clin Exp Rheumatol1996; 15:S99–102.
24.
NimmerjahnFRavetchJV. The antiinflammatory activity of IgG: The intravenous IgG paradox. J Exp Med2007; 204:11–5.
25.
LeontyevDKatsmanYMaXZMiescherSKäsermannFBranchDR. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion2012; 52:1799–805.
26.
MassoudAHGuayJShalabyKH. Intravenous immunoglobulin attenuates airway inflammation through induction of forkhead box protein 3-positive regulatory T cells. J Allergy Clin Immunol2012; 129:1656–65.
27.
KazatchkineMDKaveriSV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med2001; 345:747–55.
28.
AnderssonUBjörkLSkansén-SaphirUAnderssonJ. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev1994; 139:21–42.
29.
CrowARSongSSempleJWFreedmanJLazarusAH. A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?Blood2007; 109:155–8.
30.
DimitrovJDLacroix-DesmazesSKaveriSVVassilevTL. Insight into the mechanism of the acquired antibody autoreactivity. Autoimm Rev2008; 7:410–14.
31.
RoncaroloMGGregoriSBattagliaMBacchettaRFleischhauerKLevingsMK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev2006; 212:28–50.
